← SynDRA
LOTEPREDNOL ETABONATE
SynDRA canonical compound SYN0023242 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | NR3C1 |
|---|
| Mechanism of action | Glucocorticoid receptor agonist |
|---|
| Indication | conjunctivitis |
|---|
| Disease area | ophthalmology |
|---|
All known targets
Mechanisms of action (all sources)
- Phospholipase inhibitor
- NR3C1 AGONIST
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ESR1
- PGR
- NR1I2
- ABCB11
- MLNR
- HRH2
- HRH3
- HTR1A
- HTR2A
- HTR2B
- HTR2C
- HTR3A
- KCNH2
- MAOA
- MC3R
- NPY1R
- HDAC6
- OPRD1
- OPRK1
- OPRM1
- PDE3A
- PDE4D
- PTGS2
- SLC29A1
- SLC6A2
- SLC6A3
- SLC6A4
- HRH1
- GHSR
- ABCC3
- EDNRA
- ADORA1
- ADORA2A
- ADORA3
- ADRA1A
- ADRA2A
- ADRA2B
- ADRA2C
- ADRB1
- ADRB2
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ANDR
- CP3A4
- NF2L2
- PPARG
- PRGR
Drug classes
- Corticosteroid Hormone Receptor Agonists
- Corticosteroid
- Anti-Allergic Agents
ATC classes
- S01B · ANTIINFLAMMATORY AGENTS
Cross-references
Synonyms
- ALREX
- Alrex
- EYSUVIS
- Eysuvis
- INVELTYS
- Inveltys
- LOTEMAX
- LOTEMAX SM
- LOTEPREDNOL ETABONATE AND TOBRAMYCIN
- Lotemax
- ZYLET
- lenoxin
- lotemax
- Loteprednol
- CDDD-5604
- CDDD5604
- HGP-1
- KPI-121
- P-5604
- Lotemax sm
- Loteprednol etabonate component of zylet
- Locort
- Loteflam
- Loterox
- IDR-90102
- IDR-90103
- Lotemax (TN)
- Alrex, Lotemax, Loteprednol etabonate
- Loteprednol etabonate (JAN/USAN)
- loteprednol
- CDDD 5604
- ZYLET COMPONENT LOTEPREDNOL ETABONATE
- YEH1EZ96K6
- P 5604
- HGP 1
- Airex
Reported adverse events
Look up LOTEPREDNOL ETABONATE in the interactive SynDRA portal →